Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting

Glycotope GmbH announces that it will present new data at the 2022 American Association for Cancer Research Annual Meeting, being held in New Orleans, United States, between 8-16 April 2022.

Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting

Berlin, Germany, 08 April, 2022Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present new data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, United States, between 8-16 April 2022.

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: “The data presented at AACR shows the potential of targeting GlycoTargets to increase the tumor-selectivity of antibodies. We will present two anti-GlycoTarget antibodies with markedly improved tumor-selectivity compared to protein binding antibodies resulting in reduced binding to healthy tissues or blood cells. Additionally, we will present updated in vivo efficacy data for GT-00A x IL15, our TA-MUC1-targeting IL-15 fusion antibody. GT-00A x IL15 is one of the first tumor-targeted immuno-cytokines and has the potential to significantly outperform non-targeted IL-15 immuno-cytokines offering a highly needed alternative in the treatment of several solid-tumor indications.”

Poster details are as follows:

Abstract Number: 4542 Download here as of Friday, 8 April 1pm ET / 7pm CET

Title: Carbohydrate-dependent protein binding antibodies with superior tumor-specificity
Category: Poster Section 21: Antibodies and Immune Therapies

Session Start Time: 4/10/2022 1:30:00 PM
Session End Time: 4/10/2022 5:00:00 PM

Abstract Number: 4584 Download here as of Friday, 8 April 1pm ET / 7pm CET

Abstracts are now available on AACR’s website located at www.aacr.org. E-posters will be available to registrants of the AACR Annual Meeting at 1:00 p.m. EDT on Friday, April 8

Title: Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties
Category: Poster Section 37: Therapeutic Antibodies 1

Session Start Time: 4/12/2022 9:00:00 AM
Session End Time: 4/12/2022 12:30:00 PM

Contact Information:


Glycotope GmbH
Dr. Patrik Kehler
CSO
Phone: +49 30 9489 2600
E-Mail: contact@glycotope.com

Media Contact:
Chris Gardner, Chris Welsh
Consilium Strategic Communications
Phone: +44 (0) 20 3709 5700
Email: glycotope@consilium-comms.com

About GT-00A x IL15

GT-00A x IL15 is a TA-MUC1 targeting IL-15 immuno-cytokine fusion antibody. Cytokines have long been used for cancer therapy to activate the immune system, but side effects and short half-life limit their therapeutic application. The concept of specific targeting to the tumor and tumor microenvironment to exploit the full potential of IL-15 biology is unique within the competitive field of IL-15 (super)agonists. The immuno-cytokine attracts and activates immune cells (e.g., T and NK cells) directly at the tumor site thereby turning an “immune desert” into a “hot” tumor and inducing tumor cell lysis. A comprehensive non-clinical data package is available.

About Glycotope

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins.

Visit www.glycotope.com


MORE ON THIS TOPIC